Skip to content

Advertisement

  • Poster presentation
  • Open Access

High plasma Amyloid β42 and P-tau in mild cognitive impairment as risk factors of the disease

  • 1, 2,
  • 2,
  • 2,
  • 1,
  • 3,
  • 4 and
  • 1
Annals of General Psychiatry20087(Suppl 1):S182

https://doi.org/10.1186/1744-859X-7-S1-S182

Published: 17 April 2008

Keywords

  • Peptide
  • Animal Model
  • Plasma Level
  • Normal Control
  • Mild Cognitive Impairment

Background

Patients with mild cognitive impairment (MCI) is reported to develop Alzheimer's disease (AD) at the rate of 12% per year, greatly exceeding the 1% to 2% incidence of normal controls. Several studies have shown an increase in plasma Aβ42 in MCI compared to normal and AD patients. The efficiency of Aβ peptides elimination in earlier stages of AD has proven in animal models. We found no study measuring phospho-tau (p-tau) level in plasma.

Materials and methods

We measured the plasma level of Aβ42 and p-tau181 in 7 patients with MCI, 29 AD and 16 normal controls who had also underwent brain SPECT imaging.

Results

Plasma levels of Aβ42 and p-tau were significantly higher in MCI (57.9±33.3 pg/ml) (44.5± 91.5pg/ml) comparing AD (16.3±15.5pg/ml) (3.4±10.7pg/ml) and normal group (12±7.7pg/ml) (00 pg/ml) (p<0.000) (p<0.010) respectively.

P-tau was not detectable in normal group but p-tau was detectable in (57%) (4/7) of patients with MCI and 4 patients with AD. 3 patients with MCI who had high plasma Aβ42 and detectable p-tau too, had shown bilateral

Posterior temporoparietal hypoperfusion and one showed not-characteristic perfusion defects in SPECT.

Conclusions

Since high plasma Aβ42 and p-tau in our patients with MCI were accompanied by perfusion defect characteristic of AD which is said to be a sign of the progression of MCI to AD, we suggest the evaluation of plasma Aβ42 and p-tau as the risk factors of the disease in patients with MCI.

Authors’ Affiliations

(1)
First Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece
(2)
Department of Nuclear Medicine, AHEPA University Hospital, Thessaloniki, Greece
(3)
Department of Biochemistry, AHEPA University Hospital, Thessaloniki, Greece
(4)
Department of Radiology, AHEPA University Hospital, Thessaloniki, Greece

Copyright

© Sedaghat et al.; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement